

5.90.052

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2024
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	November 19, 2021
<b>Subject:</b>	Susvimo	<b>Page:</b>	1 of 6

---

**Last Review Date:** March 8, 2024

---

## Susvimo

### Description

Susvimo (ranibizumab) for intravitreal use via Susvimo ocular implant

---

### Background

Susvimo (ranibizumab) is a vascular endothelial growth factor (VEGF) inhibitor used to treat patients with wet (neovascular) age-related macular degeneration (AMD). The VEGF inhibitors block the effects of VEGF-A and prevents the interaction of VEGF-A with its receptors (VEGFR<sub>1</sub> and VEGFR<sub>2</sub>) on the surface of endothelial cells, reducing endothelial cell growth, vascular leakage, and new blood vessel formation (1).

### Regulatory Status

FDA-approved indication: Susvimo (ranibizumab), a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor (1).

Susvimo has a boxed warning regarding a 3-fold higher rate of endophthalmitis than the monthly intravitreal injections of ranibizumab (1).

Susvimo is contraindicated in ocular or periocular infections and in patients with active intraocular inflammation (1).

Susvimo has additional warnings for the following: rhegmatogenous retinal detachment, implant dislocation, vitreous hemorrhage, conjunctival erosion or retraction, conjunctival bleb,

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2024
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	November 19, 2021
<b>Subject:</b>	Susvimo	<b>Page:</b>	2 of 6

---

postoperative decrease in visual acuity, air bubbles causing improper filling of the implant, and deflection of the implant (1).

The Susvimo initial fill and ocular implant insertion and implant removal procedures must be performed under aseptic conditions by a physician experienced in vitreoretinal surgery. The Susvimo ocular implant must be surgically implanted in the eye or removed from the eye (if medically necessary) in an operating room using aseptic technique. Susvimo refill-exchange procedures must be performed under aseptic conditions by a physician experienced in ophthalmic surgery (1).

The recommended dose of Susvimo is 2 mg (0.02 mL of 100 mg/mL solution) continuously delivered via the Susvimo implant with refills every 24 weeks (approximately 6 months). Supplemental treatment with 0.5 mg intravitreal ranibizumab injection may be administered in the affected eye if clinically necessary (1).

Safety and effectiveness of Susvimo in pediatric patients less than 18 years of age have not been established (1).

---

## Related policies

Bevacizumab, Lucentis, VEGF Inhibitors

## Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Susvimo may be considered **medically necessary** if the conditions indicated below are met.

Susvimo may be considered **investigational** for all other indications.

## Prior-Approval Requirements

**Age** 18 years of age or older

### Diagnosis

Patient must have the following:

1. Neovascular (wet) age-related macular degeneration (AMD)

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2024
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	November 19, 2021
<b>Subject:</b>	Susvimo	<b>Page:</b>	3 of 6

---

**AND ALL** of the following:

- a. Patient has previously responded to at least **TWO** intravitreal injections of a VEGF inhibitor (see Appendix 1)
- b. Documented baseline visual acuity test
- c. Prescriber agrees to monitor for endophthalmitis
- d. **NO** ocular or periocular infection
- e. **NO** active intraocular inflammation
- f. **NOT** used in combination with other vascular endothelial growth factor (VEGF) inhibitors (see Appendix 1) other than Lucentis (ranibizumab)

---

## Prior – Approval *Renewal* Requirements

**Age** 18 years of age or older

### Diagnosis

Patient must have the following:

1. Neovascular (wet) age-related macular degeneration (AMD)

**AND ALL** of the following:

- a. Patient has demonstrated a positive clinical response to therapy (e.g., improvement or maintenance in best corrected visual acuity [BCVA] or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss)
- b. Prescriber agrees to monitor for endophthalmitis
- c. **NO** ocular or periocular infection
- d. **NO** active intraocular inflammation
- e. **NOT** used in combination with other vascular endothelial growth factor (VEGF) inhibitors (see Appendix 1) other than Lucentis (ranibizumab)

## Policy Guidelines

### Pre - PA Allowance

None

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2024
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	November 19, 2021
<b>Subject:</b>	Susvimo	<b>Page:</b>	4 of 6

---

## Prior - Approval Limits

**Quantity** 4 single-dose vials

**Duration** 12 months

---

## Prior – Approval *Renewal* Limits

Same as above

## Rationale

### Summary

Susvimo (ranibizumab) prevents the binding and activation of VEGF receptors leading to a decrease in the neovascularization and vascular permeability associated with neovascular AMD. Patients on Susvimo must be monitored for endophthalmitis. Susvimo is an intravitreal injection for use via Susvimo ocular implant. Safety and effectiveness in pediatric patients less than 18 years of age have not been established (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Susvimo while maintaining optimal therapeutic outcomes.

### References

1. Susvimo [package insert]. South San Francisco, CA: Genentech, Inc.; April 2022.

## Policy History

Date	Action
November 2021	Addition to PA
December 2021	Annual review
March 2022	Annual review. Vabysmo added to Appendix 1
June 2022	Annual review
September 2022	Annual review and reference update
December 2022	Annual review
June 2023	Annual review

# 5.90.052

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2024
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	November 19, 2021
<b>Subject:</b>	Susvimo	<b>Page:</b>	5 of 6

---

December 2023      Annual review

March 2024        Annual review

## [Keywords](#)

---

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 8, 2024 and is effective on April 1, 2024.**

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2024
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	November 19, 2021
<b>Subject:</b>	Susvimo	<b>Page:</b>	6 of 6

---

## Appendix 1 - List of VEGF Inhibitors for Ocular Indications

Generic Name	Brand Name
aflibercept	Eylea
bevacizumab	Avastin
brolocizumab-dbl	Beovu
faricimab-svoa	Vabysmo
ranibizumab*	Lucentis*
ranibizumab	Susvimo

\*Dual therapy is allowed with Lucentis (ranibizumab)